Market Overview

JMP Calls BioCryst's Oral Kallikrein 'Potential Game Changer,' Believes ViroPharma, Shire Could Be Interested


Investors in shares of BioCryst Pharma (NASDAQ: BCRX) are pushing the stock nearly 3 percent higher Wednesday, potentially on the heels of some positive comments from JMP Securities' Liisa Bayko. Bayko boosted her price target on BioCryst shares from $5 to $8. The analyst maintains a Market Outperform rating on the stock.

Bayko noted "Investors see BioCryst's oral kallikrein program as a potential game changer in HAE." The company is currently prepping the commencement of a Phase 2a POC trial for kallikrein. "Amongst a healthy degree of competition in the HAE prophylaxis market, we believe even modest efficacy could carve out a meaningful market opportunity for BioCryst given the number of patients who may consider initiating prophylaxis if there were an oral option. Additionally, a second drug candidate is targeting better bioavailability, which could deliver better efficacy in fewer doses."

If efficacy is demonstrated, the JMP analyst said, "...we believe there could be interest from potential acquirers, including established players such as Shire (NASDAQ: SHPG) and ViroPharma (NASDAQ: VPHM) or companies focused on rare diseases seeking to participate in this market."

Bayko suggests "...owning shares of BioCryst ahead of the POC data in 1Q14..."

With BioCryst shares last trading around $6.63, Bayko's new target represents potential upside of almost 21 percent.

Latest Ratings for BCRX

Nov 2019UpgradesNeutralBuy
May 2019DowngradesOutperformSector Perform
Apr 2019MaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for BCRX
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target FDA Analyst Ratings


Related Articles (BCRX + SHPG)

View Comments and Join the Discussion!

Latest Ratings

TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Three ETFs For Account Surplus Countries

Syria Holds Markets Hostage For Time Being